Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Industry Reports
2 min read
siRNA Drug Amvuttra Patent Research and Practical Operation Guide(1)
29 August 2024
Alnylam announced on June 14, 2022, that its siRNA drug Amvuttra® (vutrisiran) was approved by the FDA for the treatment of polyneuropathy with hereditary transthyretin-mediated amyloidosis (hATTR) in adults.
Latest Hotspot
4 min read
Roche's PiaSky receives EU approval as the first monthly subcutaneous therapy for PNH patients
29 August 2024
Roche has announced that the European Commission has granted approval for PiaSky® (crovalimab), an innovative recycling monoclonal antibody that targets the complement protein C5.
Pharma Frontiers
10 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 29
29 August 2024
Aug 29th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Latest Hotspot
2 min read
Phase 1 study outcomes of exidavnemab published in The Journal of Clinical Pharmacology
29 August 2024
BioArctic AB revealed the publication of the findings from two phase-1 trials involving exidavnemab(ABBV-0805) in The Journal of Clinical Pharmacology.
DrugDeal Decode
6 min read
How to quickly read pharmaceutical company financial reports?
28 August 2024
This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.
Pharma Frontiers
9 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 28
28 August 2024
Aug 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Latest Hotspot
4 min read
SIFI Gains European Commission Nod for AKANTIOR®
27 August 2024
SIFI revealed that the European Commission has granted approval for AKANTIOR® (polihexanide) for managing acanthamoeba keratitis (AK) in both adults and children aged 12 and over.
Pharma Frontiers
7 min read
Pharma Frontiers: Daily Digest of Global Pharmaceutical News – Aug 27
27 August 2024
Aug 27th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Latest Hotspot
3 min read
EU Commission Approves Celltrion’s SteQeyma®, a Stelara® Biosimilar, for Chronic Inflammatory Disorders
27 August 2024
The European Commission grants approval to Celltrion’s SteQeyma® (CT-P43), a biosimilar version of Stelara® (ustekinumab), for treating several chronic inflammatory disorders.
Latest Hotspot
3 min read
FDA Approves Galapagos' IND for Phase 1/2 Trial of GLPG5101, a CD19 CAR-T Therapy
27 August 2024
Galapagos reveals FDA approval of its IND application for the Phase 1/2 ATALANTA-1 trial of CD19 CAR-T therapy, GLPG5101, in non-Hodgkin lymphoma that has relapsed or is refractory.
Latest Hotspot
3 min read
Moderna Gains European Commission Nod for RSV Vaccine mRESVIA(R)
27 August 2024
Moderna, Inc. (NASDAQ:MRNA) reported that the European Commission (EC) has approved mRESVIA® (mRNA-1345), an mRNA vaccine targeting respiratory syncytial virus (RSV), for marketing.
Latest Hotspot
3 min read
Mabwell Receives CDE Nod for New Nectin-4 ADC, Set to Start Phase III Cervical Cancer Trial
27 August 2024
The company will commence a Phase III clinical trial aiming to investigate the effectiveness and safety of 9MW2821 in individuals with recurrent or metastatic cervical cancer (CC).